Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK).
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Connect Biopharma Holdings (CNTB)
Lake Street analyst Thomas Flaten maintained a Buy rating on Connect Biopharma Holdings today and set a price target of $9.00. The company’s shares closed last Monday at $3.00.
According to TipRanks.com, Flaten is a 4-star analyst with an average return of
Connect Biopharma Holdings has an analyst consensus of Strong Buy, with a price target consensus of $8.67.
See today’s best-performing stocks on TipRanks >>
Neumora Therapeutics, Inc. (NMRA)
Needham analyst Ami Fadia maintained a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $8.00. The company’s shares closed last Monday at $1.95, close to its 52-week low of $1.02.
According to TipRanks.com, Fadia is a 5-star analyst with an average return of
Neumora Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $10.80.
Merck & Company (MRK)
In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Merck & Company, with a price target of $137.00. The company’s shares closed last Monday at $121.16.
According to TipRanks.com, Scala is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $132.25 average price target, a 10.5% upside from current levels. In a report issued on March 18, Bernstein also maintained a Hold rating on the stock with a EUR112.00 price target.
Read More on CNTB:
